Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
|Juntendo Shizuoka Hospital-Juntendo, University School of Medicine, Japan|
|ScientificTracks Abstracts: Oncol Cancer Case Rep|
|Previously, we found that the ERC (Expressed in Renal Carcinoma) gene was preferentially expressed in renal cancers in the Eker rat. Furthermore, we subsequently confirmed that ERC is a homolog of the human mesothelin gene, a gene that is strongly expressed in normal mesothelial cells, mesotheliomas, and non-mucinous ovarian carcinomas. The ERC/mesothelin gene (MSLN) encodes a 71kDa precursor protein, which is cleaved to yield 31kDa N-terminal (N-ERC/mesothelin) and 40 kDa C-terminal (C-ERC/mesothelin) proteins. N-ERC/mesothelin (also known as megakaryocyte-potentiating factor; MPF) is a soluble protein and is released into the extracellular space and blood. C-ERC/mesothelin is a glycoprotein that is tethered to the cell surface by a glycosylphosphatidylinositol anchor. C-ERC/mesothelin expression of tumor by immunohistochemistry can be correlated with patient’s survival in several human cancers. Soluble Mesothelin-Related Peptide (SMRP) has proven to be a promising biomarker in the sera of patients with mesothelioma and ovarian cancer. As for secreted N-ERC/mesothelin, we previously devised a novel Enzyme-Linked Immunosorbent Assay (ELISA) system for determining its concentration in serum and showed that it is useful for diagnosing human mesothelioma and ovarian cancer. In addition, we demonstrated that C-ERC/mesothelin was expressed in gastric cancer and pancreatic cancer tissues. Meanwhile, increased serum N-ERC/mesothelin concentrations are not specific to these patients with gastric cancer or pancreatic cancer. Although N-ERC/mesothelin is established as a reliable marker for mesothelioma, N-ERC/mesothelin is not useful as a diagnostic marker of gastric cancer and pancreatic cancer.|
Tomoaki Ito received the MD in 2000 and the PhD in Medical Science from Juntendo University, Tokyo, Japan. He completed Post-doctoral studies from Stanford University School of Medicine. He is an Assistant Professor of Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine, Shizuoka, Japan. His research interests include oncology and cancer biomarker.
Email: [email protected]
|PDF | HTML|